Comparable stake leader
Octagon Capital Advisors LP
SEC ownership of PRECISION BIOSCIENCES INC
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001357874.
Disclosed value leader
Octagon Capital Advisors LP
Comparable rows
50/50
Latest evidence
31 Mar 2026
- Public ticker
- DTIL on Nasdaq
- Parsed ownership sources
- 13F, 13D/G, and 3/4/5
- Largest SEC-reported holder
- Octagon Capital Advisors LP
- Latest 13D/G holder
- Octagon Capital Advisors LP
- Latest parsed ownership date
- 31 Mar 2026
- Issuer CIK
- 0001357874
- Issuer location
- Durham, NC
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of PRECISION BIOSCIENCES INC (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Octagon Capital Advisors LP
Disclosed value leader
Octagon Capital Advisors LP
Comparable rows
50/50
Latest evidence
31 Mar 2026
13F
13D/G
3/4/5
Lead comparable stake: 10%
13D/G row: Octagon Capital Advisors LP
Showing 1-8 of 50 holder rows.
Quick read
Octagon Capital Advisors LP leads the comparable SEC ownership view at 10%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Octagon Capital Advisors LP's linked filing trail.
Comparable ownership
Top 5
Octagon Capital Advisors LP
10%
Readout Capital, LP
9.4%
Aberdeen Group plc
8.9%
Bleichroeder LP
8.2%
Empery Asset Management, LP
7.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Octagon Capital Advisors LP |
13F
13D/G
Company
|
10%
from 13D/G
|
$12,302,026
2,236,732 shares
|
— | 31 Mar 2026 |
| Readout Capital, LP |
13D/G
Matthew Smith
|
9.4%
|
$4,980,934
1,119,311 shares
|
+$829,645 | 30 Jun 2025 |
| Aberdeen Group plc |
13F
13D/G
Company
|
8.9%
from 13D/G
|
$12,265,979
2,230,178 shares
|
— | 31 Mar 2026 |
| Bleichroeder LP |
13F
13D/G
Company
|
8.2%
from 13D/G
|
$9,143,750
1,662,500 shares
|
— | 31 Mar 2026 |
| Empery Asset Management, LP |
13F
13D/G
Company
|
7.6%
from 13D/G
|
$10,828,835
1,968,879 shares
|
— | 31 Mar 2026 |
| Weinstein Benjamin |
13D/G
|
5.2%
|
$2,107,956
395,489 shares
|
$0 | 18 Mar 2025 |
| Lynx1 Capital Management LP |
13F
13D/G
Company
|
4.1%
from 13D/G
|
$5,418,122
985,113 shares
|
— | 31 Mar 2026 |
| NOVARTIS PHARMA AG |
3/4/5
13D/G
10%+ Owner
|
3.7%
from 13D/G
|
$4,590,753
12,407,440 shares
|
— | 15 Jun 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$447,272.
Buys
$82,058
Insiders: 4
Sells
$529,330
Insiders: 4
Net
-$447,272
Shares: -109,889
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 17,939
Shares: 127,828
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 7,081 | 107,624 | $33,714 | $431,271 | -$397,557 |
| 6-9 | 4,100 | 5,377 | $20,265 | $34,897 | -$14,632 |
| 9-12 | 6,758 | 14,827 | $28,080 | $63,163 | -$35,083 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-19 of 19 reporting-owner rows connected to PRECISION BIOSCIENCES INC. Open a relationship link for the CIK-to-CIK filing trail.
Rows
19
Largest Forms 3/4/5 holder
NOVARTIS PHARMA AG
Net 12M change
-$447,272
Latest report
03 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| NOVARTIS PHARMA AG | 10%+ Owner | $4,590,753 | Mixed | 15 Jun 2022 | ||
| Derek Jantz | Chief Scientific Officer, Director | $1,509,439 | Mixed | 07 Jun 2022 | ||
| Michael Amoroso | President and CEO, Director | $934,625 | -$246,183 | -21% | Filing P/S | 01 Jun 2026 |
| Matthew R. Kane | President and CEO, Director | $749,324 | Mixed | 07 Jun 2021 | ||
| J. Jefferson Smith | Chief Research Officer | $500,236 | -$60,018 | -11% | Mixed | 01 Jun 2026 |
| John Alexander Kelly | Chief Financial Officer | $483,390 | -$164,220 | -25% | Filing P/S | 01 Jun 2026 |
| Kevin Buehler | Director | $388,165 | +$21,116 | +5.8% | Mixed | 03 Jun 2026 |
| Geno J. Germano | Director | $364,768 | +$14,160 | +4% | Mixed | 03 Jun 2026 |
| Melinda Brown | Director | $361,815 | +$20,673 | +6.1% | Mixed | 03 Jun 2026 |
| Stanley Frankel | Director | $340,541 | +$26,109 | +8.3% | Mixed | 03 Jun 2026 |
| Shari Lisa Pire | Director | $310,566 | Mixed | 03 Jun 2026 | ||
| Dario Scimeca | General Counsel and Secretary | $216,794 | -$58,909 | -21% | Filing P/S | 01 Jun 2026 |
| Samuel C. Wadsworth | Director | $161,277 | Mixed | 04 Jun 2024 | ||
| Alan List | Chief Medical Officer | $56,440 | Mixed | 01 May 2024 | ||
| David S. Thomson | Chief Operating Officer | $41,260 | Mixed | 23 Jun 2021 | ||
| Shane Barton | VP & Corporate Controller | $12,418 | Mixed | 07 Jun 2023 | ||
| Fayaz Khazi | CEO of Elo Life Systems | $8,880 | Mixed | 07 Jun 2021 | ||
| Shalini Sharp | Director | Mixed | 10 May 2021 | |||
| Raymond F. Schinazi | Director | Mixed | 10 May 2022 |
Recent insider transactions for PRECISION BIOSCIENCES INC
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Melinda Brown | DTIL | Restricted Stock Units | Award | 20,979 | 20,979 | 03 Jun 2026 | Direct | |||
| Stanley Frankel | DTIL | Restricted Stock Units | Award | 20,979 | 20,979 | 03 Jun 2026 | Direct | |||
| Geno J. Germano | DTIL | Restricted Stock Units | Award | 20,979 | 20,979 | 03 Jun 2026 | Direct | |||
| Shari Lisa Pire | DTIL | Restricted Stock Units | Award | 20,979 | 20,979 | 03 Jun 2026 | Direct | |||
| Kevin Buehler | DTIL | Restricted Stock Units | Award | 20,979 | 20,979 | 03 Jun 2026 | Direct | |||
| J. Jefferson Smith | DTIL | Restricted Stock Units | Award | 57,389 | 57,389 | 01 Jun 2026 | Direct | |||
| Dario Scimeca | DTIL | Restricted Stock Units | Award | 107,604 | 107,604 | 01 Jun 2026 | Direct | |||
| John Alexander Kelly | DTIL | Restricted Stock Units | Award | 193,688 | 193,688 | 01 Jun 2026 | Direct | |||
| Michael Amoroso | DTIL | Restricted Stock Units | Award | 573,888 | 573,888 | 01 Jun 2026 | Direct | |||
| Kevin Buehler | DTIL | Common Stock | Options Exercise | 74.6% | 21,000 | 49,137 | 20 May 2026 | Direct | ||
| Kevin Buehler | DTIL | Restricted Stock Units | Options Exercise | -100% | -21,000 | 0 | 20 May 2026 | Direct | ||
| Stanley R. Frankel | DTIL | Common Stock | Options Exercise | 107.8% | 21,000 | 40,478 | 20 May 2026 | Direct | ||
| Stanley R. Frankel | DTIL | Restricted Stock Units | Options Exercise | -100% | -21,000 | 0 | 20 May 2026 | Direct | ||
| Melinda Brown | DTIL | Common Stock | Options Exercise | 90% | 21,000 | 44,346 | 20 May 2026 | Direct | ||
| Melinda Brown | DTIL | Restricted Stock Units | Options Exercise | -100% | -21,000 | 0 | 20 May 2026 | Direct | ||
| Shari Lisa Pire | DTIL | Common Stock | Options Exercise | 149.7% | 21,000 | 35,028 | 20 May 2026 | Direct | ||
| Shari Lisa Pire | DTIL | Restricted Stock Units | Options Exercise | -100% | -21,000 | 0 | 20 May 2026 | Direct | ||
| Geno J. Germano | DTIL | Common Stock | Options Exercise | 87.9% | 21,000 | 44,883 | 20 May 2026 | Direct | ||
| Geno J. Germano | DTIL | Restricted Stock Units | Options Exercise | -100% | -21,000 | 0 | 20 May 2026 | Direct | ||
| Michael Amoroso | DTIL | Common Stock | Sale | -7.79% | $78,947 | $3.84 | -20,559 | 243,392 | 18 Feb 2026 | Direct |
| John Alexander Kelly | DTIL | Common Stock | Sale | -6.08% | $31,292 | $3.84 | -8,149 | 125,883 | 18 Feb 2026 | Direct |
| Dario Scimeca | DTIL | Common Stock | Sale | -8.02% | $18,912 | $3.84 | -4,925 | 56,457 | 18 Feb 2026 | Direct |
| J. Jefferson Smith | DTIL | Common Stock | Sale | -3.88% | $18,912 | $3.84 | -4,925 | 121,926 | 18 Feb 2026 | Direct |
| Michael Amoroso | DTIL | Common Stock | Options Exercise | 34.6% | 67,797 | 263,951 | 17 Feb 2026 | Direct | ||
| Michael Amoroso | DTIL | Restricted Stock Units | Options Exercise | -33.3% | -67,797 | 135,593 | 17 Feb 2026 | Direct | ||
| John Alexander Kelly | DTIL | Common Stock | Options Exercise | 25.9% | 27,584 | 134,032 | 17 Feb 2026 | Direct | ||
| John Alexander Kelly | DTIL | Restricted Stock Units | Options Exercise | -33.3% | -27,584 | 55,166 | 17 Feb 2026 | Direct | ||
| Dario Scimeca | DTIL | Common Stock | Options Exercise | 37.3% | 16,667 | 61,382 | 17 Feb 2026 | Direct | ||
| Dario Scimeca | DTIL | Restricted Stock Units | Options Exercise | -33.3% | -16,667 | 33,333 | 17 Feb 2026 | Direct | ||
| J. Jefferson Smith | DTIL | Common Stock | Options Exercise | 15.1% | 16,667 | 126,851 | 17 Feb 2026 | Direct | ||
| J. Jefferson Smith | DTIL | Restricted Stock Units | Options Exercise | -33.3% | -16,667 | 33,333 | 17 Feb 2026 | Direct | ||
| Michael Amoroso | DTIL | Common Stock | Sale | -15.1% | $145,112 | $4.17 | -34,799 | 196,154 | 22 Jan 2026 | Direct |
| Dario Scimeca | DTIL | Common Stock | Sale | -16.5% | $35,682 | $4.03 | -8,854 | 44,715 | 21 Jan 2026 | Direct |
| John Alexander Kelly | DTIL | Common Stock | Sale | -12.5% | $61,308 | $4.03 | -15,213 | 106,448 | 21 Jan 2026 | Direct |
| J. Jefferson Smith | DTIL | Common Stock | Sale | -8.47% | $41,106 | $4.03 | -10,200 | 110,184 | 21 Jan 2026 | Direct |
| J. Jefferson Smith | DTIL | Common Stock | Options Exercise | 15.6% | 16,219 | 120,384 | 21 Jan 2026 | Direct | ||
| Michael Amoroso | DTIL | Common Stock | Options Exercise | 99.8% | 115,378 | 230,953 | 20 Jan 2026 | Direct | ||
| Michael Amoroso | DTIL | Restricted Stock Units | Options Exercise | -100% | -115,378 | 0 | 20 Jan 2026 | Direct | ||
| Dario Scimeca | DTIL | Common Stock | Options Exercise | 89.6% | 25,311 | 53,569 | 20 Jan 2026 | Direct | ||
| Dario Scimeca | DTIL | Restricted Stock Units | Options Exercise | -100% | -25,311 | 0 | 20 Jan 2026 | Direct | ||
| John Alexander Kelly | DTIL | Common Stock | Options Exercise | 57.4% | 44,363 | 121,661 | 20 Jan 2026 | Direct | ||
| John Alexander Kelly | DTIL | Restricted Stock Units | Options Exercise | -100% | -44,363 | 0 | 20 Jan 2026 | Direct | ||
| J. Jefferson Smith | DTIL | Common Stock | Options Exercise | 14.2% | 12,947 | 104,165 | 20 Jan 2026 | Direct | ||
| J. Jefferson Smith | DTIL | Restricted Stock Units | Options Exercise | -100% | -29,166 | 0 | 20 Jan 2026 | Direct | ||
| Geno J. Germano | DTIL | Common Stock | Purchase | 14.4% | $14,160 | $4.72 | 3,000 | 23,883 | 16 Dec 2025 | Direct |
| Stanley R. Frankel | DTIL | Common Stock | Purchase | 16.1% | $12,690 | $4.70 | 2,700 | 19,478 | 16 Dec 2025 | Direct |
| Melinda Brown | DTIL | Common Stock | Purchase | 6.29% | $6,864 | $4.97 | 1,381 | 23,346 | 15 Dec 2025 | Direct |
| John Alexander Kelly | DTIL | Common Stock | Sale | -1.66% | $8,456 | $6.49 | -1,303 | 77,298 | 03 Nov 2025 | Direct |
| Dario Scimeca | DTIL | Common Stock | Sale | -2.3% | $4,316 | $6.49 | -665 | 28,258 | 03 Nov 2025 | Direct |
| Michael Amoroso | DTIL | Common Stock | Sale | -2.87% | $22,124 | $6.49 | -3,409 | 115,575 | 03 Nov 2025 | Direct |
* marks a reported price that did not pass the local price check.